A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
NCT06208878 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 70
Last updated 2025-08-14
Summary
This study will evaluate the long-term safety and efficacy of CRISPR CAR T cellular therapies
Conditions
- Hematologic Malignancy
- Solid Malignancy
Interventions
- OTHER
-
Non Interventional
Safety and Efficacy Assessment
Sponsors & Collaborators
-
CRISPR Therapeutics AG
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-11-22
- Primary Completion
- 2038-08-31
- Completion
- 2038-08-31
Countries
- United States
- Australia
- Canada
- Germany
Study Locations
More Related Trials
-
Neuroimaging and Biomarkers of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy
NCT07075523 ·Status: RECRUITING
-
CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM
NCT05168423 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
NCT04099797 ·Status: RECRUITING ·Phase: PHASE1
-
Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies
NCT02813837 ·Status: UNKNOWN ·Phase: NA
-
CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR
NCT02331693 ·Status: UNKNOWN ·Phase: PHASE1
-
GD2/CD70 Bi-specific CAR-T Cell Therapy
NCT05438368 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia
NCT06622694 ·Status: RECRUITING ·Phase: PHASE1
-
Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
NCT06056921 ·Status: RECRUITING ·Phase: PHASE1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
NCT07340853 ·Status: RECRUITING ·Phase: PHASE1
-
Molecular-genetic Characterization in Patients Undergoing CAR-T Cell Infusion
NCT05807789 ·Status: RECRUITING
-
Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.
NCT06836505 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma
NCT05420493 ·Status: RECRUITING ·Phase: PHASE1
-
Chimeric Antigen Receptor T-Cell (CAR-T) Cells in Patients With R/R T-LBL
NCT05554575 ·Status: UNKNOWN ·Phase: PHASE1
-
Tris-CAR-T Cell Therapy for Recurrent Glioblastoma
NCT05577091 ·Status: RECRUITING ·Phase: PHASE1
-
CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors
NCT06254807 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation
NCT07117305 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia
NCT07008872 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma
NCT05909527 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma
NCT05059912 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
NCT06703892 ·Status: RECRUITING ·Phase: PHASE1
-
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
NCT05795595 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
DLL3 CAR-T Therapy Targeting Brain Tumors
NCT07180927 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
CAR-T Cells Targeting Autoimmune Diseases
NCT05459870 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer
NCT06215950 ·Status: RECRUITING ·Phase: PHASE1
-
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
NCT04660929 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1